Trans-European Drug Information

Last updated
Trans-European Drug Information network
AbbreviationTEDI
Founded20 June 2008;16 years ago (2008-06-20)
Focus Drug checking
Area served
Europe
Website https://www.tedinetwork.org/

The Trans-European Drug Information (TEDI) project is a European database compiling information from different drug checking services located on the European continent. The non-governmental organizations feeding into the database are referred to as the TEDI network.

Contents

History

The first drug checking service in Europe opened in 1986 in Amsterdam, allowing drug users to analyze the chemical composition of illicit substances that they consume. [1] In the following years, a number of nonprofit organizations present in various other drug scenes [2] in several countries (including in Austria, France, Germany, the Netherlands, Portugal, Spain, and Switzerland) set up drug checking services. [3]

In 2011, a database was created for to centralize information from these services and allow for the sharing of alerts (for example on new adulterants in illicit substances [4] or circulation of novel psychoactive substance [5] ) and the monitoring of drug markets across borders. [6]

Between 2008 and 2013, organizations member of the TEDI network analyzed more than 45,000 samples of recreational drugs, showing similarities and discrepancies between areas of the European continent in terms of purity, formulation, or prices. [7]

The TEDI project

The project and the network are hosted by the Polish nonprofit TEDI Nightlife Empowerment & Well-being Network (also known as NEW net or SaferNightlife).[ citation needed ]

Network

As of 2022, the TEDI network was integrated by 20 organizations across 13 countries (Austria, Belgium, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Portugal, Slovenia, Spain, Switzerland, and the United Kingdom). [8] A team of professionals from various fields (substance use disorder prevention workers, pharmacists, chemists, etc.) across network member organizations constitutes the TEDI project's team. [6]

Database

The aims of the Trans-European Drug Information project are to collect, monitor and analyze the evolution of the European recreational drug market trends, and to regularly report the findings. Since 2011, the database has facilitated the centralization and comparison of information collected at the local level.[ citation needed ]

The TEDI database also feeds into the early warning system of the European Union Drugs Agency (EUDA, formerly EMCDDA). EUDA and the TEDI network also collaborate on the organization of conferences [9] and trainings. [10]

In 2019, the mobile application TripApp was launched by a consortium or organizations, sharing in real-time alerts [11] from the TEDI database, in addition to connecting app users with local harm reduction providers. [12] The app received an award from the Council of Europe in 2021. [13]

Guidelines

As part of the project, guidelines and methodological recommendations have been published, such as:

See also

Related Research Articles

<span class="mw-page-title-main">Supervised injection site</span> Medical facility

Supervised injection sites (SIS) or drug consumption rooms (DCRs) are a health and social response to drug-related problems. They are fixed or mobile spaces where people who use drugs are provided with sterile drug use equipment and can use illicit drugs under the supervision of trained staff. They are usually located in areas where there is an open drug scene and where injecting in public places is common. The primary target group for DCR services are people who engage in risky drug use.

The European Coalition for Just and Effective Drug Policies (ENCOD), originally European NGO Council On Drugs and development, is a network of European non-governmental organisations and citizens concerned with the impact of current international drug policies on the lives of the most affected sectors in Europe and the Global South. Since 1994 they have been working to advocate more just and effective drugs control policies, which include an integrated solution for all problems related to the global drugs phenomenon.

<span class="mw-page-title-main">European Union Drugs Agency</span> Agency on illicit drugs of the European Union, formerly "EMCDDA"

The European Union Drugs Agency (EUDA), known until 2024 as the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), is an agency of the European Union headquartered in Lisbon, Portugal, and established in 1993.

<span class="mw-page-title-main">Reagent testing</span> Tests for authentication of psychoactive drugs, and detection of adulterants

Reagent testing is one of the processes used to identify substances contained within a pill, usually illicit substances. With the increased prevalence of drugs being available in their pure forms, the terms "drug checking" or "pill testing" may also be used, although these terms usually refer to testing with a wider variety of techniques covered by drug checking.

Adult lifetime cannabis use by country is the lifetime prevalence of cannabis use among all adults in surveys among the general population. Lifetime prevalence means any use of cannabis during a person's life.

The drug policy of Portugal, informally called the "drug strategy", was put in place in 2000, and came into effect in July 2001. Its purpose was to reduce the number of new HIV/AIDS cases in the country, as it was estimated around half of new cases came from injection drug use.

<span class="mw-page-title-main">25I-NBF</span> Chemical compound

25I-NBF is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor, with bias towards the β-arrestin 2 coupled signalling pathway. It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).

<span class="mw-page-title-main">Nortilidine</span> Chemical compound

Nortilidine is the major active metabolite of tilidine. It is formed from tilidine by demethylation in the liver. The racemate has opioid analgesic effects roughly equivalent in potency to that of morphine. The (1R,2S) isomer has NMDA antagonist activity. The drug also acts as a dopamine reuptake inhibitor. The reversed-ester of nortilidine is also known, as is the corresponding analogue with the cyclohexene ring replaced by cyclopentane, which have almost identical properties to nortilidine.

The European Association of Libraries and Information Services on Addictions (ELISAD) – previously called, until end of 2011, European Association of Libraries and Information Services on Alcohol and other Drugs – was a European non-governmental and non-profit making social network of libraries, documentation centres and information services situated in Europe and specialised in alcohol, drugs, tobacco and all other behavioural addictions.

Council of the European Union decisions on designer drugs. Council of the European Union issued a set of decisions on 7 designer drugs to make them subject to control measures and criminal provisions.

<span class="mw-page-title-main">3-(4-Hydroxymethylbenzoyl)-1-pentylindole</span> Chemical compound

3-(4-Hydroxymethylbenzoyl)-1-pentylindole is a synthetic cannabinoid. It is planned to be scheduled in Poland. It has been reported to the EMCDDA and Europol for the first time in 2010 under the terms of European Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances.

Responsible drug use seeks to maximize the benefits and minimize the risks associated with psychoactive drug use. For illegal psychoactive drugs that are not diverted prescription controlled substances, some critics believe that illegal recreational drug use is inherently irresponsible, due to the unpredictable and unmonitored strength and purity of the drugs and the risks of addiction, infection, and other side effects.

<span class="mw-page-title-main">Bluelight (web forum)</span> Web forum and research portal

Bluelight is a web-forum, research portal, online community, and non-profit organization dedicated to harm reduction in drug use. Its userbase includes current and former substance users, academic researchers, drug policy activists, and mental health advocates. It is believed to be the largest online international drug discussion website in the world. As of February 2024, the website claims over 465,000 registered members.

<span class="mw-page-title-main">MDMB-CHMICA</span> Chemical compound

'MDMB-CHMICAa' is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.

Drug checking or pill testing is a way to reduce the harm from drug consumption by allowing users to find out the content and purity of substances that they intend to consume. This enables users to make safer choices: to avoid more dangerous substances, to use smaller quantities, and to avoid dangerous combinations.

<span class="mw-page-title-main">Difludiazepam</span> Chemical compound

Difludiazepam (Ro07-4065) is a benzodiazepine derivative which is the 2',6'-difluoro derivative of fludiazepam. It was invented in the 1970s but was never marketed, and has been used as a research tool to help determine the shape and function of the GABAA receptors, at which it has an IC50 of 4.1nM. Difludiazepam has subsequently been sold as a designer drug, and was first notified to the EMCDDA by Swedish authorities in 2017.

<span class="mw-page-title-main">MDMB-4en-PINACA</span> Chemical compound

MDMB-4en-PINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. MDMB-4en-PINACA was first identified in Europe in 2017. In 2021, MDMB-4en-PINACA was the most common synthetic cannabinoid identified by the Drug Enforcement Administration in the United States. MDMB-4en-PINACA differs from 5F-MDMB-PINACA due to replacement of 5-fluoropentyl with a pent-4-ene moiety (4-en).

<span class="mw-page-title-main">CUMYL-CBMINACA</span> Chemical compound

CUMYL-CBMINACA (SGT-277) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Germany in February 2020. It is illegal in Finland.

<span class="mw-page-title-main">Pompidou Group</span>

The Council of Europe International Cooperation Group on Drugs and Addiction, also known as Pompidou Group is the co-operation platform of the Council of Europe on matters of drug policy currently composed of 42 countries. It was established as an ad'hoc inter-governmental platform in 1971 until its incorporation into the Council of Europe in 1980. Its headquarters are in Strasbourg, France.

References

  1. 1 2 Bücheli, Alexander; the Trans-European Drug Information project (2013). Drug Checking Consultation and Counselling Guidelines (PDF). Barcelona: Nightlife Empowerment & Wellbeing Implementation Project.
  2. ↑ Caldicott, David (22 February 2017). "Yes, we can do on-the-spot drug testing quickly and safely". The Conversation. Retrieved 2022-09-01.
  3. ↑ Trans European Drugs Information (TEDI) workgroup (2011). Factsheet on Drug Checking in Europe (PDF). Brussels: Nightlife, Empowerment & Well-being Implementation Project.
  4. ↑ Zaami, S (2019-11-01). "New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard". European Review for Medical and Pharmacological Sciences. 23 (22): 9681–9690. doi:10.26355/eurrev_201911_19529. ISSN   2284-0729. PMID   31799633. S2CID   208621146.
  5. ↑ Oomen, Pieter E.; Schori, Dominique; Tögel-Lins, Karsten; Acreman, Dean; Chenorhokian, Sevag; Luf, Anton; Karden, Alexandra; Paulos, Carlos; Fornero, Elisa; Gerace, Enrico; Koning, Raoul P. J.; Galindo, Liliana; Smit-Rigter, Laura A.; Measham, Fiona; Ventura, Mireia (2022-02-01). "Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services". International Journal of Drug Policy. 100: 103493. doi:10.1016/j.drugpo.2021.103493. ISSN   0955-3959. PMID   34687992. S2CID   239482166.
  6. 1 2 The Trans-European Drug Information project (2022). "About us – TEDI". tedinetwork.org. Retrieved 2022-09-01.
  7. ↑ Brunt, Tibor M.; Nagy, Constanze; Bücheli, Alexander; Martins, Daniel; Ugarte, Miren; Beduwe, Cécile; Ventura Vilamala, Mireia (2017). "Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project". Drug Testing and Analysis. 9 (2): 188–198. doi:10.1002/dta.1954. PMID   26888408.
  8. ↑ The Trans-European Drug Information project (2022-03-31). "Story map: "Fieldwork drug checking services from 13 different European countries"". ArcGIS StoryMaps. Retrieved 2022-09-01.
  9. ↑ European Monitoring Centre for Drugs and Drug Addiction (2019-10-22). "International symposium on drug checking". emcdda.europa.eu. Retrieved 2022-09-01.
  10. ↑ European Monitoring Centre for Drugs and Drug Addiction (2021-12-08). "EMCDDA-TEDI network meeting of European drug checking services | www.emcdda.europa.eu". www.emcdda.europa.eu. Retrieved 2022-09-01.
  11. ↑ "TripApp - Apps on Google Play". play.google.com. Retrieved 2022-09-01.
  12. ↑ Lekhtman, Alexander (2019-12-31). "The 'TripApp' Helps You Make Safer Choices About Your Drug Use". FilterMag. Retrieved 2022-09-01.
  13. ↑ Pompidou Group, Newsroom (2021). "European Drug Prevention Prize: winning projects from Belgium, Poland and Lithuania". Council of Europe .
  14. ↑ "Guidelines". TEDI project. 2015.
  15. ↑ Creixell, Maria (2022-03-31). "The European network of drug checking services TEDI is launching a website to share information on the drug markets". ABD. Retrieved 2022-09-01.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.